Financial Advisors Network Inc. Has $305,000 Holdings in Cencora, Inc. $COR

Financial Advisors Network Inc. trimmed its position in shares of Cencora, Inc. (NYSE:COR) by 47.9% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,098 shares of the company’s stock after selling 1,011 shares during the quarter. Financial Advisors Network Inc.’s holdings in Cencora were worth $305,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also made changes to their positions in the company. Exchange Traded Concepts LLC lifted its stake in Cencora by 4.5% in the first quarter. Exchange Traded Concepts LLC now owns 1,104 shares of the company’s stock valued at $307,000 after acquiring an additional 48 shares during the last quarter. Dynamic Advisor Solutions LLC raised its holdings in shares of Cencora by 6.4% during the 1st quarter. Dynamic Advisor Solutions LLC now owns 1,535 shares of the company’s stock valued at $427,000 after purchasing an additional 93 shares in the last quarter. GAMMA Investing LLC lifted its stake in shares of Cencora by 57.0% in the 1st quarter. GAMMA Investing LLC now owns 5,748 shares of the company’s stock valued at $1,598,000 after purchasing an additional 2,087 shares during the last quarter. Golden State Wealth Management LLC boosted its holdings in Cencora by 157.6% in the first quarter. Golden State Wealth Management LLC now owns 170 shares of the company’s stock worth $47,000 after purchasing an additional 104 shares in the last quarter. Finally, Leith Wheeler Investment Counsel Ltd. increased its position in Cencora by 5.2% during the fourth quarter. Leith Wheeler Investment Counsel Ltd. now owns 82,952 shares of the company’s stock worth $18,638,000 after buying an additional 4,126 shares during the last quarter. Institutional investors own 97.52% of the company’s stock.

Insider Activity at Cencora

In other Cencora news, CEO Robert P. Mauch sold 4,968 shares of the business’s stock in a transaction on Friday, July 18th. The shares were sold at an average price of $294.11, for a total value of $1,461,138.48. Following the sale, the chief executive officer owned 42,351 shares of the company’s stock, valued at $12,455,852.61. The trade was a 10.50% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Chairman Steven H. Collis sold 14,578 shares of the stock in a transaction on Tuesday, July 22nd. The shares were sold at an average price of $292.67, for a total transaction of $4,266,543.26. Following the completion of the transaction, the chairman owned 309,913 shares of the company’s stock, valued at approximately $90,702,237.71. This represents a 4.49% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 34,125 shares of company stock worth $9,993,789 in the last three months. 10.80% of the stock is owned by insiders.

Cencora Trading Down 0.8%

Shares of COR stock opened at $290.45 on Tuesday. The firm has a market capitalization of $56.31 billion, a P/E ratio of 29.88, a price-to-earnings-growth ratio of 1.39 and a beta of 0.58. Cencora, Inc. has a 1 year low of $218.65 and a 1 year high of $309.35. The firm’s fifty day simple moving average is $292.83 and its 200 day simple moving average is $279.55. The company has a current ratio of 0.90, a quick ratio of 0.53 and a debt-to-equity ratio of 3.64.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, August 6th. The company reported $4.00 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.79 by $0.21. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The company had revenue of $80.66 billion for the quarter, compared to the consensus estimate of $80.34 billion. During the same quarter in the previous year, the firm posted $3.34 EPS. The business’s revenue was up 8.7% compared to the same quarter last year. As a group, sell-side analysts predict that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Friday, August 15th will be issued a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a dividend yield of 0.8%. The ex-dividend date of this dividend is Friday, August 15th. Cencora’s dividend payout ratio (DPR) is presently 22.63%.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on COR shares. Robert W. Baird upped their price target on Cencora from $314.00 to $350.00 and gave the stock an “outperform” rating in a research note on Thursday, May 8th. Citigroup boosted their target price on Cencora from $330.00 to $355.00 and gave the stock a “buy” rating in a report on Thursday, May 8th. UBS Group upped their target price on Cencora from $298.00 to $335.00 and gave the stock a “buy” rating in a research report on Tuesday, April 29th. Morgan Stanley set a $330.00 price target on shares of Cencora and gave the company an “equal weight” rating in a research report on Wednesday, July 16th. Finally, Wells Fargo & Company upped their price objective on shares of Cencora from $337.00 to $354.00 and gave the stock an “overweight” rating in a report on Wednesday, August 13th. Three analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $311.25.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.